Telehealth on the rise, page-2316

I don't know where this thread talk is going, but I believe the goal posts have shifted and application via the FDA Emergency Use Authorisation should at least be considered. As I said, GMV have done this and they have had success with their product in remote monitoring. FWIW I emailed Dr. Joseph Kvedar at the ATA about this.

"Hello, I am hoping you can pass this message on to Dr Joseph Kvedar.I am a shareholder in ResApp and am wondering if the ResApp diagnostic platform wouldn't be perfect for the FDA's Emergency Use Authorisation? We all know about the results of the US clinical trials for pneumonia and it also has been explained the FDA weren't satisfied about the benefits vs. risks of the diagnostic AI. However with the insidious progression of COVID surely it is worth applying again? Thank you for your consideration."